Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - Zentalis Pharmaceuticals, Inc. | zentalis10-qq12021ex321.htm |
EX-31.2 - EX-31.2 - Zentalis Pharmaceuticals, Inc. | zentalis10-qq12021ex312.htm |
EX-31.1 - EX-31.1 - Zentalis Pharmaceuticals, Inc. | zentalis10-qq12021ex311.htm |
EX-10.4 - EX-10.4 - Zentalis Pharmaceuticals, Inc. | exhibit104-zentalisxleasex.htm |
EX-10.3 - EX-10.3 - Zentalis Pharmaceuticals, Inc. | exhibit103-zentalisx2020in.htm |
10-Q - 10-Q - Zentalis Pharmaceuticals, Inc. | zntl-20210331.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Zentalis Pharmaceuticals, Inc. (the “Company”) for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 17, 2021 | By: | /s/ Melissa B. Epperly | ||||||
Melissa B. Epperly | ||||||||
Chief Financial Officer (principal financial officer) |